Home
HelpTest Code NCDA Congenital Dyserythropoietic Anemia Gene Panel, Next-Generation Sequencing, Varies
Ordering Guidance
Multiple hematology gene panels are available. For more information, see NHHA and Subpanel Comparison Gene List.
Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.
Targeted testing for familial variants (also called site-specific or known variants testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.
Shipping Instructions
Necessary Information
1. Metabolic Hematology Next-Generation Sequencing (NGS) Patient Information is required. Testing may proceed without the patient information, however, the information aids in providing a more thorough interpretation. Ordering providers are strongly encouraged to fill out the form and send with the specimen.
2. If form not provided, include the following information with the test request: clinical diagnosis, pertinent clinical history (ie, complete blood cell count results and relevant clinical notes) and differentials based on any previous bone marrow studies, clinical or morphologic presentation.
Specimen Required
Specimen Type: Whole blood
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated
Forms
1. Metabolic Hematology Next-Generation Sequencing (NGS) Patient Information (T816) is required.
2. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing (Spanish) (T826)
3. If not ordering electronically, complete, print, and send a Benign Hematology Test Request (T755)with the specimen.
Secondary ID
619075Useful For
Confirming the diagnosis or carrier variant status of genes associated with congenital dyserythropoietic anemia
Identifying variants within genes associated with phenotypic severity, allowing for predictive testing and further genetic counseling
Genetics Test Information
This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 6 genes associated with congenital dyserythropoietic anemia: CDAN1, CDIN1 (C15orf41), GATA1, KIF23, KLF1, and SEC23B. See Method Description for additional details.
Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for congenital dyserythropoietic anemia.
Special Instructions
Method Name
Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing
Reporting Name
CDA Sequencing, NGSSpecimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Varies | ||
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Next-generation sequencing is a methodology that can interrogate large regions of genomic DNA in a single assay. The presence and pattern of gene variants can provide critical diagnostic, prognostic, and therapeutic information for managing physicians.
This panel aids in the diagnosis and genetic counseling of individuals with clinical or familial features of congenital dyserythropoietic anemia (CDA). CDA is a disorder of ineffective erythropoiesis clinically subdivided into subtypes with various phenotypic findings that segregate into different gene associations.(1-6) These disorders have distinctive cytopathologic findings consisting of nuclear abnormalities in bone marrow erythroid precursors. Types I and II CDA are inherited in an autosomal recessive pattern, whereas types III and IV are autosomal dominant.
Reference Values
|
An interpretive report will be provided. |
Interpretation
All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(7) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.
Day(s) Performed
Varies
Report Available
28 to 42 daysSpecimen Retention Time
Whole blood: 2 weeks (if available); Extracted DNA: 3 monthsPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81479
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| NCDA | CDA Sequencing, NGS | 103734-0 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 619076 | Test Description | 62364-5 |
| 619077 | Specimen | 31208-2 |
| 619078 | Source | 31208-2 |
| 619079 | Result Summary | 50397-9 |
| 619080 | Result | 82939-0 |
| 619081 | Interpretation | 69047-9 |
| 619082 | Additional Results | 82939-0 |
| 619083 | Resources | 99622-3 |
| 619084 | Additional Information | 48767-8 |
| 619085 | Method | 85069-3 |
| 619086 | Genes Analyzed | 82939-0 |
| 619087 | Disclaimer | 62364-5 |
| 619088 | Released By | 18771-6 |